Literature DB >> 29132522

Nonalcoholic Fatty Liver Disease.

Patrick H Sweet1, Teresa Khoo2, Steven Nguyen2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) defines a condition of hepatic steatosis with or without hepatic injury. NAFLD is increasing in prevalence worldwide and presents a public health burden. Most patients are asymptomatic, although some present with fatigue and right upper quadrant pain. NAFLD is discovered incidentally when patients have elevated liver enzymes or fatty liver is seen on imaging modalities. Imaging studies can confirm fatty deposits in the liver, but needle biopsy is needed to determine degree of inflammation. The mainstay of treatment is weight loss and controlling diabetes and hyperlipidemia. Liver transplantation is considered when disease progresses to cirrhosis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidemia; Insulin resistance; Liver disease; Metabolic disease; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Steatosis

Mesh:

Year:  2017        PMID: 29132522     DOI: 10.1016/j.pop.2017.07.003

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  18 in total

Review 1.  The Matrisome, Inflammation, and Liver Disease.

Authors:  Christine E Dolin; Gavin E Arteel
Journal:  Semin Liver Dis       Date:  2020-01-07       Impact factor: 6.115

2.  Association Between Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Cohort Study.

Authors:  Ru Zhang; Qing Guan; Mengting Zhang; Yajie Ding; Zongzhe Tang; Hongliang Wang; Wei Zhang; Yue Chen; Rong Jiang; Yan Cui; Jie Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-10-19       Impact factor: 3.249

3.  Increased butyrate priming in the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic reprogramming in a mouse model of Gulf War Illness.

Authors:  Ratanesh Kumar Seth; Diana Kimono; Firas Alhasson; Sutapa Sarkar; Muayad Albadrani; Stephen K Lasley; Ronnie Horner; Patricia Janulewicz; Mitzi Nagarkatti; Prakash Nagarkatti; Kimberly Sullivan; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2018-05-09       Impact factor: 4.219

4.  Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis.

Authors:  Yani Ke; Shan Liu; Zheyuan Zhang; Jie Hu
Journal:  Lipids Health Dis       Date:  2021-05-25       Impact factor: 3.876

5.  Dried mulberry fruit ameliorates cardiovascular and liver histopathological changes in high-fat diet-induced hyperlipidemic mice.

Authors:  Suriya Chaiwong; Usana Chatturong; Rachanee Chanasong; Watcharakorn Deetud; Kittiwoot To-On; Supaporn Puntheeranurak; Ekarin Chulikorn; Tanwarat Kajsongkram; Veerada Raksanoh; Kroekkiat Chinda; Nanteetip Limpeanchob; Kanittaporn Trisat; Julintorn Somran; Nitra Nuengchamnong; Piya Prajumwong; Krongkarn Chootip
Journal:  J Tradit Complement Med       Date:  2021-02-12

6.  Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development.

Authors:  Yan Xu; Jichun Han; Jinjin Dong; Xiangcheng Fan; Yuanyuan Cai; Jing Li; Tao Wang; Jia Zhou; Jing Shang
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

7.  Effect of lipid metabolism disorder on liver function in patients with malignant tumors after chemotherapy: a case-control study.

Authors:  Yan Sun; Nie Zhang; Yun-Long Ding; Li-Jiang Yu; Jun Cai; Wu Yang; Wang-Kun Lu; Jia-Li Niu
Journal:  Lipids Health Dis       Date:  2019-05-10       Impact factor: 3.876

8.  Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Julio Cesar Fernandez-Travieso; Ivan Rodriguez-Perez; Caridad Ruenes-Domech; Jose lIlnait-Ferrer; Lilia Fernandez-Dorta; Sarahi Mendoza-Castano
Journal:  Gastroenterology Res       Date:  2020-04-22

9.  Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4.

Authors:  Lu Huang; Wei Ding; Ming-Qiang Wang; Zheng-Gen Wang; Hong-Hui Chen; Wen Chen; Qiong Yang; Ting-Na Lu; Qing Yang; Ji-Man He
Journal:  J Int Med Res       Date:  2019-08-05       Impact factor: 1.671

10.  Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?

Authors:  Hayatul Najaa Miptah; Anis Safura Ramli; Mariam Mohamad; Hilwati Hashim; Zahirah Tharek
Journal:  BMC Fam Pract       Date:  2020-11-20       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.